The article presents pathogenical and clinical justification of administration of angiotensin II receptor blockers, in particular valsartan, in recipients of kidney transplant for the purpose to prevention and inhibition of progression its chronic rejection

Keywords: chronic transplant nephropathy, valsartan, angiotensin II receptor blockers